Most immunology textbooks treat cytotoxic killing as the exclusive province of blood-derived cells — T cells, natural killer cells, neutrophils. A discovery published in Cell challenges that framework by identifying a glandular cell type that executes immune defense through a fundamentally different and previously unrecognized mechanism, one rooted not in the hematopoietic lineage but in hormone-sensing epithelial tissue.
Working in planarian flatworms — a widely used regeneration model — researchers characterized a novel cell population they named ruptoblasts, which undergo a form of cell death termed ruptosis. Rather than the orderly packaging of apoptosis or the membrane rupture of pyroptosis, ruptosis is explosive: the cell physically detonates, releasing diffusible cytotoxic agents capable of destroying adjacent cells, bacteria, and even mammalian cells within minutes. The trigger is activin, a TGF-β superfamily hormone already known for roles in development and reproduction, here acting as an inflammatory cytokine. Excessive activin — induced experimentally via protein injection, genetic chimerism, or actual bacterial infection — initiates ruptosis. Ablating ruptoblasts reduced inflammation but impaired bacterial clearance, demonstrating genuine bidirectional immune function. Mechanistically, the explosive cell death depends on calcium release from the endoplasmic reticulum combined with cytoskeleton-driven signal amplification, distinguishing it from necroptosis, NETosis, and other known death modalities. Ruptoblast-like cells were identified across diverse basal bilaterians, suggesting the system predates vertebrate adaptive immunity by hundreds of millions of years.
The finding carries several layers of significance for immunity research. It expands the conceptual boundary of innate immunity beyond hematopoietic cells entirely, raising the question of whether analogous glandular cytotoxic populations exist in vertebrates — including humans — and have simply been overlooked. The hormone-immunity coupling is particularly provocative: activin is elevated in human inflammatory conditions including sepsis and cancer cachexia, and its newly described role as a ruptosis trigger invites reinterpretation of those pathophysiologies. Key limitations include the planarian model's phylogenetic distance from mammals and the absence of direct human-cell evidence. This appears paradigm-shifting for evolutionary immunology, though translation to clinical relevance requires substantial further work.